Harman Finochem Limited Allopurinol Export Data — India (DGFT 2022–2026)

Name: Harman Finochem Limited Allopurinol Export Records India — #6 Exporter, 80 Shipments, $3.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Allopurinol

India Pharmaceutical Trade Intelligence

$492.9M223 Suppliers102 CountriesHS 30049099

ExportsIndia → UNITED STATES52.1%India → NEW ZEALAND26.9%

ImportsUNITED STATES → India$130.2K GERMANY → India$110.4K

#1 Supplier: IPCA LABORATORIES #1 Buyer: UNICHEM PHARMACEUTICALS

Harman Finochem Limited — Allopurinol Exporter #6 | $3.4M Trade Value | TransData Nexus | TransData Nexus

Harman Finochem Limited — Allopurinol Exporter Profile

Indian Pharmaceutical Exporter · #6 for Allopurinol · $3.4M export value · DGFT Verified

Harman Finochem Limited is the #6 Indian exporter of Allopurinol with $3.4M in export value and 80 verified shipments. Harman Finochem Limited holds a 0.7% market share in Allopurinol exports across 4 countries. The company exports 3 pharmaceutical products worth $11.4M across 3 therapeutic categories.

Harman Finochem Limited — Allopurinol Export Profile: Buyers & Destinations

Harman Finochem Limited Allopurinol export treemap — buyers and destination countries | TransData Nexus

Where Does Harman Finochem Limited Export Allopurinol?

Country	Value	Shipments	Share
UNITED KINGDOM	$1.0M	32	38.9%
UNITED STATES	$964.3K	30	35.8%
GERMANY	$538.4K	15	20.0%
MALTA	$142.4K	3	5.3%

Who Are the Top Buyers of Allopurinol from Harman Finochem Limited?

Buyer	Country	Value	Orders
TO THE ORDER	UNITED KINGDOM	$167.4K	4

Harman Finochem Limited supplies Allopurinol to 1 buyers globally. The largest buyer is TO THE ORDER (UNITED KINGDOM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Allopurinol Formulations Does Harman Finochem Limited Export?

Product Description / Formulation	Value	Shipments
ALLOPURINOL 300MG TABLETS	$227.6K	7
ALLOPURINOL 300MG TABLETS (28)S	$199.8K	4
ALLOPURINOL 100MG TABLETS (28)S	$184.4K	4
ALLOPURINOL 100MG TABLETS	$130.7K	4
ALLOPURINOL 300MG TABLETSNOS	$100.2K	4
ALLOPURINOL 300MG TABLETS 28 S	$100.0K	2
Allopurinol Heumann 300mg Tab	$100.0K	2
Allopurinol Heumann 300mgTab 680 BOX PACKED ON 44 PALLETS	$100.0K	2
ALLOPURINOL TABLETS USP 100MG	$89.2K	2
ALLOPURINOL 100MG TABLETS (500)S	$81.8K	3

Harman Finochem Limited exports 45 distinct Allopurinol formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ALLOPURINOL 300MG TABLETS with 7 shipments worth $227.6K.

Regulatory Requirements: Exporting Allopurinol to Key Markets

What Harman Finochem Limited must comply with to export Allopurinol to its top destination countries

United Kingdom — MHRA

Approval Process

Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.

Timeline: 12–15 months

GMP & Export Requirements

UK GMP compliance; MHRA inspection of manufacturing site

Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release

Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.

United States — FDA

Approval Process

ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.

Timeline: 10–18 months for ANDA approval

GMP & Export Requirements

FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA

Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system

Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.

Germany — BfArM/EMA

Approval Process

Marketing Authorisation via Decentralized or Mutual Recognition Procedure under EU Directive 2001/83/EC. CTD Module 1–5 dossier required.

Timeline: 12–18 months via Decentralized Procedure

GMP & Export Requirements

EU GMP (EudraLex Vol. 4); GMP certificate from EU competent authority; WHO Prequalification accepted as supporting evidence

Certificate of Pharmaceutical Product (CPP) from CDSCO; Written Confirmation for API export per EU requirements; EU FMD serialization mandatory

Note: Indian manufacturers must hold EU GMP certificate. EU Falsified Medicines Directive (FMD) serialization and tamper-evident packaging mandatory.

Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.

How Does Harman Finochem Limited Compare to Nearest Allopurinol Exporters?

Exporters ranked immediately above and below #6 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
5	PAR FORMULATIONS PRIVATE LIMITED	$10.6M	211	1	$50.0K
4	SANDOZ PRIVATE LIMITED	$4.8M	97	2	$50.0K
6	HARMAN FINOCHEM LIMITED ★	$3.4M	80	4	$42.5K
7	ZYDUS LIFESCIENCES LIMITED	$2.7M	55	1	$48.3K
8	CAPLIN POINT LABORATORIES LIMITED	$1.6M	90	6	$18.2K

Harman Finochem Limited ranks #6 among 223 Indian Allopurinol exporters. Average shipment value of $42.5K compared to the market average of $517.9K. The closest competitors by value are PAR FORMULATIONS PRIVATE LIMITED and SANDOZ PRIVATE LIMITED.

Which Indian Ports Ship Allopurinol Exports?

Port	Shipments	% Share
NHAVA SHEVA SEA (INNSA1)	724	16.6%
SAHAR AIR	501	11.5%
JNPT/ NHAVA SHEVA SEA	446	10.2%
SAHAR AIR CARGO ACC (INBOM4)	380	8.7%
DELHI AIR CARGO ACC (INDEL4)	308	7.1%
JNPT	261	6.0%
DELHI AIR	203	4.7%
NHAVA SHEVA SEA	134	3.1%

Geopolitical & Trade Policy Impact on Harman Finochem Limited's Allopurinol Exports

The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Harman Finochem. The Israel-Iran conflict has led to disruptions in the Red Sea shipping routes, causing increased shipping costs and delays. These maritime disruptions have particularly impacted time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management. (pharmaceuticalcommerce.com)

In the United States, recent tariff escalations have introduced additional complexities. The imposition of 100% tariffs on branded or patented pharmaceutical products from India, effective October 1, 2025, poses a significant challenge. While generic drugs may remain largely unaffected, the overall trade environment has become more volatile, requiring exporters to reassess their market strategies. (itisbl.com)

Conversely, the India-European Union Free Trade Agreement, signed on January 27, 2026, offers a positive development. The agreement eliminates tariffs on most European pharmaceutical exports to India and vice versa, potentially enhancing market access and competitiveness for Indian exporters in the EU market. (en.wikipedia.org)

Harman Finochem Limited — Regulatory Compliance & Quality Standards

The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with stringent quality and compliance standards becoming the norm. For Indian exporters, adherence to FDA, WHO, and EU Good Manufacturing Practices (GMP) is imperative to maintain market access. Companies with robust quality systems and proactive compliance cultures are better positioned to navigate this landscape. Smaller players may face challenges due to rising compliance costs, potentially leading to industry consolidation. (lupinnews.com)

While specific regulatory events involving Harman Finochem are not detailed in the available sources, the company's sustained export performance suggests a commitment to maintaining high-quality standards. Continuous investment in quality assurance and compliance infrastructure will be crucial for sustaining and expanding its export footprint.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Allopurinol shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Harman Finochem Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 80 individual customs records matching Harman Finochem Limited exporting Allopurinol, covering 45 formulations to 4 countries via 1 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 102+ countries, 378+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Allopurinol

Allopurinol

Harman Finochem Limited — Allopurinol Exporter Profile

Harman Finochem Limited — Allopurinol Export Profile: Buyers & Destinations

Where Does Harman Finochem Limited Export Allopurinol?

Who Are the Top Buyers of Allopurinol from Harman Finochem Limited?

What Is India's Total Allopurinol Export Value and How Much Does Harman Finochem Limited Contribute?

What Is the Average Shipment Value for Harman Finochem Limited's Allopurinol Exports?

How Does Harman Finochem Limited Compare to Other Indian Allopurinol Exporters?

What Allopurinol Formulations Does Harman Finochem Limited Export?

Regulatory Requirements: Exporting Allopurinol to Key Markets

United Kingdom — MHRA

United States — FDA

Germany — BfArM/EMA

How Does Harman Finochem Limited Compare to Nearest Allopurinol Exporters?

Which Indian Ports Ship Allopurinol Exports?

Geopolitical & Trade Policy Impact on Harman Finochem Limited's Allopurinol Exports

Harman Finochem Limited — Regulatory Compliance & Quality Standards

About Harman Finochem Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Allopurinol Export Data from Harman Finochem Limited

Allopurinol Stats

Company Overview

Top Products by Harman Finochem Limited

Related Analysis

Need Detailed Export Data?

Data Source